Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$4.725
−$0.915 · -16.22%
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Previous close
$4.725
−$0.915 · -16.22%
After-hours
$4.65
−$0.075 · -1.59%
Oct 9, 7:57 PM ET
Regular session · ET · Market data may be delayed.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Day range
Current $4.725
52-week range
Current $4.725
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
36
Expensive
Sentiment
56
Mixed
Risk
66
High Risk
Momentum
23
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Day range
Current $4.725
52-week range
Current $4.725
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.16M USD | 9.36M USD | 2.53M USD | 4.8K USD | — |
| Cost of goods sold | 4.73M USD | 5.98M USD | 1.74M USD | 467 USD | 4.82K USD |
| Gross profit | 1.43M USD | 3.38M USD | 791.62K USD | 4.34K USD | −4.82K USD |
| Research and development | 2.09M USD | 1.78M USD | 1.73M USD | 1.52M USD | 1.14M USD |
| Selling, general, and administrative | 9.91M USD | 9.94M USD | 6.79M USD | 2.48M USD | 1.07M USD |
| Operating expenses | 12M USD | 12.33M USD | 8.77M USD | 4.02M USD | 2.2M USD |
| Interest income | 23.39K USD | 17.61K USD | 122.13K USD | 46.71K USD | 424 USD |
| Interest expense | 44.37K USD | 92.48K USD | 37.13K USD | 2.53M USD | 1M USD |
| Depreciation and amortization | 504.84K USD | 605.64K USD | 249.59K USD | 10.18K USD | 4.82K USD |
| Operating income | −10.57M USD | −8.95M USD | −7.97M USD | −4.01M USD | −2.21M USD |
| Net income | −14.91M USD | −9.04M USD | −7.94M USD | −8.15M USD | −6.33M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 24, 2026 | 1:15 | — | — |
Stock split | Sep 19, 2025 | 1:30 | — | — |
Effective Aug 24, 2026
1:15
Effective Sep 19, 2025
1:30
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
